RadNet, Inc. (RDNT)
OvervaluedFundamental
25
Price
$68.94
Market Cap
$5.43B
Part 1 · What the company is worth
Overview
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretations of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$2.27B
Trailing 12 months (through 6/30/2026)
Net Income
$-21M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
-
Total Equity
$1.09B
Total Liabilities
$2.40B
Current Ratio
1.48
Interest Coverage
0.99
Debt/EBITDA
10.20
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$53.26
Current Price
$68.94
Margin of Safety
-29.4%
Fair Value Range
$34.62 - $71.90
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-1.7%
P/B Ratio
4.95
P/FCF
-
Gross Margin
-
ROIC
1.6%
Profitability Radar
Value Creation (Economic Moat)
ROIC
1.6%
WACC
9.6%
ROIC − WACC
-8.1 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (6)
- Price CAGR 27.50%
- Debt/Equity ratio
- Current Ratio
- Revenue Growth 5Y 13.7%
- Analyst Consensus 93% Buy
- Earnings Surprise avg 3.7%
Failed (13)
- EPS shows upward trend
- ROIC 1.6%
- P/B Ratio 4.95
- Operating Margin 3.1%
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- DCF valuation (Overvalued)
- ROE -1.9%
- Share Dilution 6.8%
- Net Margin Trend -0.9% vs -0.8%
- Piotroski F-Score 3/9
Unavailable (8)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Issuing new shares, diluting ownership
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Dr. Howard G. Berger M.D. | Chairman, President & CEO | 79 |
| Mr. Mark D. Stolper | Executive VP & CFO | 54 |
| Mr. Mital Patel | Executive VP & COO | 39 |
| Mr. Norman R. Hames | President & CEO of Western Operations | 69 |
| Mr. Stephen M. Forthuber | President & CEO of Eastern Operations | 64 |
| Dr. Alma Gregory Sorensen M.D. | Executive VP, Chief Strategy Officer & Director | 63 |
| Ms. Susan Hollabaugh | Chief Information Officer | - |
| Mr. David Jeffrey Katz Esq. | Executive VP, Chief Legal Officer & Corporate Secretary | 61 |
| Mr. David Manheim | Senior VP & Chief Compliance Officer | - |
| Mr. Michael M. Murdock | Executive Vice President of Mergers & Acquisitions | 70 |
Audit Risk
8
Board Risk
8
Compensation Risk
7
Shareholder Rights Risk
2
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-03-02
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-10
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-08-14
via SEC EDGAR
Income History
via SEC EDGAR
Latest News
Recent headlines for RDNT, sourced from Markets Gazette.
- 3/2/2026NEUTRALRadNet (RDNT) Q4 2025 Earnings Call Transcript
The transcript for RadNet Inc.'s (RDNT) Q4 2025 earnings call is now available to investors. While access to such documents is crucial for understanding the company's financial performance and future outlook, the current lack of specific content details prevents an immediate assessment of market impact. Analysts and investors are awaiting a review of key data, management statements, and projections to evaluate RadNet's operational and strategic health. Earnings calls are pivotal moments for grasping growth trends, profit margins, and any potential challenges the company might face in the diagnostic imaging services sector. Without the content, the signal remains neutral, pending further insights.
- 3/2/2026NEUTRALRadNet Earnings Review: Q4 Summary
Markets Gazette notes the announcement of RadNet's Q4 earnings review. While the title suggests an upcoming analysis of the company's financial performance, the provided article lacks specific details regarding the results, such as revenue figures, earnings per share, or future projections. This absence of concrete data prevents investors from assessing RadNet's current financial health or anticipating potential market movements. Traders are eagerly awaiting further information to formulate informed investment strategies.
via Markets Gazette